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(57) ABSTRACT 
The invention provides a method of promoting apoptosis of 
human glioblastoma multiforme (GBM) tumor cells. The 
method comprises isolating GBM tumor cells from a human 
brain biopsy specimen, isolating human neural stem cells 
(HNSCs) from the biopsy specimen, transforming the iso-
lated HNSCs with an operative PEX gene, and exposing 
GBM tumor cells to the transformed HNSCs to thereby pro-
mote apoptosis of the tumor cells mediated by the expressed 
PEX gene. 
4 Claims, 4 Drawing Sheets 
(4 of 4 Drawing Sheet(s) Filed in Color) 
U.S. Patent Aug. 27, 2013 Sheet 1of4 US 8,518,698 Bl 
U.S. Patent Aug. 27, 2013 Sheet 2 of 4 US 8,518,698 Bl 
U.S. Patent Aug. 27, 2013 Sheet 3 of 4 US 8,518,698 Bl 
U.S. Patent Aug. 27, 2013 Sheet 4 of 4 US 8,518,698 Bl 
US 8,518,698 Bl 
1 
METHOD OF PROMOTING APOPTOSIS OF 
GLIOBLASTOMA TUMOR CELLS 
RELATED APPLICATION 
2 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides a method of promoting apoptosis in 
This application claims priority from provisional applica-
tion Ser. No. 60/948,277, which was filed on 6 Jul. 2007, and 
which is incorporated herein by reference in its entirety. 
5 human glioblastoma multiforme tumor cells (GBMTCs) by 
treating them with PEX transformed HNSCs. The present 
invention provides one of the initial steps in development of 
an effective treatment of GBM through the use of the patient's 
FIELD OF THE INVENTION 
The present invention relates to the field of brain cancer 
and, more particularly, to a treatment which promotes 
destruction of brain tumor cells. 
10 
own PEX gene transfected HNSCs. 
The present invention provides a method of promoting 
apoptosis of human glioblastoma multiforme (GBM) tumor 
cells. The method comprises isolating 
GBM tumor cells from a human brain biopsy specimen and 
also isolating human neural stem cells (HNSCs) from the 
BACKGROUND OF THE INVENTION 
15 biopsy specimen. The method then calls for transforming the 
isolated HNSCs with a PEX gene. Following transformation, 
the method continues by contacting GBM tumor cells (GB-
MTCs) with the transformed HNSCs to thereby promote 
apoptosis of the tumor cells. Those skilled in the art will 
Patients diagnosed with Glioblastoma multiforme (GBM) 
only survive a median time of sixteen (16) months through 
extensive neurosurgery and chemotherapy along with radia-
tion therapy. Research has demonstrated that within a time-
frame of five (5) days HNSCs are able to migrate next to the 
brain tumors in mice. Therefore, it may be concluded that the 
tumor itself along with surrounding tissue should contain an 
abundant amount of HNSCs. Integrating this knowledge, a 25 
novel GBM therapy may be devised. The long range goal is to 
remove tumors from GBM patients, isolate the patient's 
Human Neural Stem Cells (HNSCs ), transfect them with the 
PEX gene within a mammalian expression vector and then 
transplant the patients original HNSCs back into the brain. 30 
PEX is part of the C-terminal fragment of MMP2 metallo-
proteinase shown to prevent "normal biding to alpha-VI 
beta-3 and disrupts angiogenesis and tumor growth". The 
central hypothesis is that after transfection of the patients 
HNSCs with the PEX gene, the cells will migrate to the site of 35 
tumor cells, express PEX and inhibit tumor growth and pos-
sibly promote apoptosis. The objectives ofthis project would 
20 recognize that the method may be carried out in vitro, but also 
may be carried out in vivo. 
be to achieve the following aims: AIM 1. Optimize a highly 
effective method for selecting all three (3) types of cells from 
a brain tumor sample. (Cancer Stem Cells, GBM Tumor 40 
Cells, Human Neural Stem Cells) AIM 2. To determine 
whether human neural stem cells transfected with the PEX 
gene effectively kill the tumor cells in vitro. AIM 3. To inves-
tigate whether PEX transfected HNSCs eliminate human 
tumor cells in vivo through mouse models. Aim 4. Perform 45 
clinical tests to determine whether PEX transfected HNSCs 
BRIEF DESCRIPTION OF THE DRAWINGS 
The application file contains at least one drawing executed 
in color. Copies of this patent or patent application publica-
tion with color drawing( s) will be provided by the Office upon 
request and payment of the necessary fee. 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 shows phase-contrast photomicrographs of the fol-
lowing: well 1 shows PEX transformed HNSCs cocultured 
with GBMTCs and well 4, below, is a control for well 1 with 
lipofectamine alone, which causes a slight level of apoptosisf; 
well 2 shows another colony of GBMTCs in coculture with 
transformed HNSCs, and well 5 shows its lipofectamine con-
trol; well 3, shows colony 3 GBMTCs cocultured with trans-
formed HNSCs and well 6 shows its lipofectamine control; 
FIG. 2 shows the same wells as shown in FIG. 1, but at a 
higher magnification; 
FIG. 3 shows GBMTCs in process of apoptosis when coc-
ultured with PEX transformed HNSCs, top left and right 
slides and bottom left and right slides are the same pictures at 
different magnifications; and 
FIG. 4 shows four photomicrographs similar to those of 
50 FIG. 3 but with different GBMTC populations. 
eliminate tumor cells in the patient. This proposed research is 
innovative, because it focuses on isolating Human Neural 
Stem Cells directly from tumor patient samples and transfect-
ing them with an anti-cancerous gene such as PEX. This 
research is expected to have the following outcomes: (1) 
Isolation of all three types of the cells from patients' brain 
tumor samples; (2) demonstration that PEX transfected 
HNSCs will effectively inhibit tumor growth in-vitro and 
in-vivo; and (3) demonstration of elimination of GBM in 55 
patients using their own HNSCs expressing PEX. This 
research is significant because it will provide a novel GBM 
therapy using the patient's own HNSCs. 
A present challenge in the treatment of glioblastoma mul-
tiforme is the fact that patients diagnosed with this disease 60 
rarely undergo surgery which effectively removes all carci-
noma cells from the site of the lesion. Therefore a solution to 
this problem may be devised through isolation of Human 
Neural Stem Cells in the patient's own tumor. Through this 
effort we can use the patients HNSCs as therapy for the 65 
patient thus eliminating any possible chance of immunore-
jection from the patient. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
US 8,518,698 Bl 
3 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 5 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 10 
The first aim of this experiment was to effectively isolate 
all three types of cells: Cancer Stem Cells, Tumor Cells and 
Human Neural Stem cells. In order to achieve the following, 
surface markers for each cell have been identified: Cancer 
Stem Cells: ABCG2, CD133 (Singh, Clarke et al. 2003; 15 
Singh, Hawkins et al. 2004; Mohan, Kandalam et al. 2006; 
Park, Selvarajah et al. 2007) Tumor Cells: Tenascin (Brack, 
Silacci et al. 2006; Silacci, Brack et al. 2006) Human Neural 
Stem Cells: MCM2, 2F7 epitope (Schubert, Coskun et al. 
2000; Mohan, Kandalam et al. 2006). Therefore using anti- 20 
bodies for each surface marker, attached to magnetic beads, 
selection was carried out using tissue from human brain 
biopses. The mixture of cells and antibody was passed 
through a magnetic tube and selection for each type of cell 
was achieved. After separation, the cells were maintained in 25 
culture in order to determine their morphology so as to pro-
vide yet another level to determine correct isolation of each 
type of cell. As a method to screen the efficiency of the surface 
markers, paraffin embedded tumor tissue was obtained. These 
samples were tested against primary antibodies that bind to 30 
these specific surface markers along with secondary antibod-
ies in order to ensure effective binding. Different secondary 
antibodies with different fluorescent tags were used to test the 
uniqueness of the surface markers proposed. We expected 
that this method, when optimized, would be an efficient way 35 
to select and categorize each type of cell from a GBM patient 
tumor sample. 
After HNSCs wee isolated from patient tumor samples and 
maintained in culture for a period of time, they were trans-
fected with the PEX gene according to the procedure shown 40 
below. 
The appended figures illustrate apoptosis of the GBMTCs 
following coculture with PEX transfected HNSCs. 
4 
pcDNA3-PEX Colony 3 [0.156 ug/ul]x25.7 ul=4 ug 
4 ug DNA: 10 ul Lipotectamine/Per Well 
6 Well Plate Format: 
X-1 X-2 X-3 X-l=Colony 1X-2=Colony2 X-3=Colony 3 
X-4 X-5 X-6 Cntrls~X-4=Lipo Alone X-5=lipo Alone 
X-6=Lipo Alone 
1. Mix DNA with 50 ul ofOpti-MEM: 
X-1: (26.2 ul DNA+23.8 ul Opti-MEM) (A-1) 
X-2: (22.9 ul DNA+27.1 ul Opti-MEM) (A-2) 
X-3: (25.7 ul DNA+24.3 ul Opti-MEM) (A-3) 
X-4throughX-6: (50ulofOpti-MEMAlone) (A-4,A-5, 
A-6) 
2 Mix Lipofectamine before using. 
3. Add Lipofeciamine in 50 ul ofOpti-MEM. (10 ul Lipo-
fectamine 40 ul of Opti-MEM) (B-1, B-2, B-3) Also: 
(B-4, B-5, B-6) 
4. Incubate this solution for 5 minutes at RT. Proceed to 
next step within 25 minutes. 
5. After 5 minutes mix AB (total volume: 100 ul). 
(Al+Bl), (A2+B2), (A3+B3), (A4+B4), (A5+B5), 
(A6+B6) 
6. Mix this solution gently and incubate for 20 minutes of 
RT (solution may appear cloudy) 
7. Add the 100 ul DNA, Lipofectamine Complex to the 
each well of the 6 well plate with cells and medium and 
mix gently by rocking back and forth. 
8. Incubate cells at 37° C. for 18-48 hours prior to testing 
for transgene expression 
9. Medium may be changed after 4-6 hours. 
That which is claimed: 
1. A method of promoting apoptosis of human glioblas-
toma multiforme (GBM) tumor cells, the method comprising: 
obtaining a diseased human brain biopsy specimen com-
prising human GBM tumor cells and normal autologous 
human neural stem cells (HNSCs ); 
isolating the normal autologous HNSCs from the diseased 
human brain biopsy specimen from the GBM tumor 
cells by use of a specific cell marker; 
transforming the isolated normal autologous HNSCs with 
an operative PEX gene; and 
exposing GBM tumor cells to the transformed normal 
autologous HNSCs to thereby promote apoptosis of the 
tumor cells mediated by the expressed PEX gene. Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
45 
2. The method of claim 1 wherein contacting exposing is 
effected in vitro. 
Transfection Protocol-For NT2 pcDNA3-PEX 
DNA : Lipotectamine 
1:2.5 
4 ug per DNA Sample 
pcDNA3-PEX Colony 1 [0.153 ug/ul]x26.2 ul=4 ug 
pcDNA3-PEX Colony 2 [0.175 ug/ul]x22.9 ul=4 ug 
3. The method of claim 1 wherein contacting exposing is 
effected in vivo. 
4. A method of producing transformed human neural stem 
50 
cells (NHSCs ), the method comprising: 
obtaining a diseased human brain biopsy specimen com-
prising human GBM tumor cells and normal autologous 
human neural stem cells (HNSCs ); 
55 
isolating the normal autologous HNSCs from the diseased 
human brain biopsy specimen from the GBM tumor 
cells by use of a specific cell marker; and 
transforming the isolated normal autologous HNSCs with 
an operative PEX gene. 
* * * * * 
